Effect of Roxadustat on Cardiometabolism

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508183-29-00

Enrollment

Registered

2024-04-12

Start date

2024-08-07

Completion date

Unknown

Last updated

2024-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome, Risk factors of cardiovascular disease

Brief summary

Plasma total cholesterol levels

Detailed description

Plasma LDL cholesterol and triglyceride levels, Insulin resistance and glucose tolerance, Body composition, Blood pressure, Skeletal muscle microcirculation

Interventions

DRUGPLACEBO

DRUGEvrenzo 70 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Plasma total cholesterol levels	—

Secondary

Measure	Time frame
Plasma LDL cholesterol and triglyceride levels, Insulin resistance and glucose tolerance, Body composition, Blood pressure, Skeletal muscle microcirculation	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026